
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.
Edward Manche, MD, of the Stanford University School of Medicine (Palo Alto, CA), speaks on results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.




